Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
Bold Solutions to Challenge AFib
Innovate

Reinventing the Technology You Rely On Everyday

A solutions-based approach to innovation, Abbott’s EP portfolio is designed to improve your procedure experience. Our approach to technology helps physicians deliver better outcomes faster by focusing on three key factors:

Download Solution Portfolio

Efficiency

Get In and Out of Your Lab in Less Time


Bold technology lets you treat more patients in less time. With Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, procedure times are reduced by an average of 34 minutes versus CMCs1

HD Grid

Know You are Doing it Right the First Time

Efficiency is not just about reduction in procedure times. Bold technology should also promise less repeat procedures and high first pass success rates. Advisor™ HD Grid Mapping Catheter has shown a 14% reduction in redo procedures compared to CMCs1 and TactiFlex™ Ablation Catheter, Sensor Enabled™ has a first pass success rate of 80.5%.2

Reduction

Exposure to Radiation Matters

With no increase to procedure time, the use of our mapping system is associated with a considerable reduction in Fluoroscopy time3, radiation dosage, and laboratory staff radiation dosage. 4

Reduced Afib Fluoro Time
REDUCED AFIB
FLUORO TIME3
Reduced Radiation Exposure in the Lab
REDUCED RADIATION
EXPOSURE IN THE LAB4

Accuracy

Boldness in treating AFib requires technology that never sacrifices accuracy or efficiency. Abbott’s EP portfolio delivers both.

EnSite OT map
EnSite X EP System signal image
Redefine signal quality when paired with a best-in-class high density mapping catheter that improves the signal to noise ratio with a noise floor of 0.01 mV6

Cleaner Maps with Automatic Removal of Outliers

EnSite™ X Software Verson 2 provides a more accurate mapping experience by automatically removing outliers.

Accuracy

Accurate contact force matters during your ablation procedures. TactiCath™ Contact Force Catheter, Sensor Enabled™ has shown 6x greater accuracy in lateral orientation for contact force ablation than the competition.7,8

Contact Force

 

Patient Outcomes

Your end goal is for your patients to be well. Abbott’s focus on creating technologies that are efficient and accurate gives you the tools you need to boldly redefine patient outcomes and change your patients’ lives. Bold solutions to challenge AFib is –

Freeing Your Patients From Atrial Arrhythmias

Advisor HD Grid and CMC data
12-month freedom from atrial arrhythmias with Advisor HD Grid Mapping Catheter, Sensor Enabled1
Agilis Nxt Steerable Sheath data
Freedom of arrhythmia at 12 months with Agilis NxT Steerable Sheath9

Driving clinical success in Paroxysmal and Persistent AFib

  • Achieving an 82.2% clinical success rate for paroxysmal AFib at one year10
  • And a 90% symptomatic success rate at 15 months - using the TactiCath Ablation Catheter, Sensor Enabled10
Chart Paroxysmal and Persistent AFib
% of patients reporting improved quality of life at 12 months following ablation11

 

Free Your Patients From the Use of OACS for Stroke Risk Reduction

With the Amplatzer™ Amulet™ Left Atrial Appendage Occluder (LAAO) you do both – not only delivering a 67% lower stroke rate, but also allowing 8 out of 10 patients to be discharged without OACs.13 Amplatzer Amulet LAAO is the only LAAO approved by the FDA that does not require use of OACs at discharge.

Chart of ischemic stroke rate reduced
Ischemic stoke rate reduced by 67% compared to predicted risk12

ELEVATE

Clinical support that elevates your
practice to meet today's challenges

Learn More
Elevate

IMPACT

Partnerships that drive
impact for the EP community

Learn More
Impact

References

  1. Day, J. D., Crandall, B., Cutler, M., Osborn, J., Miller, J., Mallender, C., & Lakkireddy, D. (2020). High Power Ultra Short Duration Ablation with HD Grid Improves Freedom from Atrial Fibrillation and Redo Procedures Compared to Circular Mapping Catheter. Journal of Atrial Fibrillation, 13(2).
  2. Abbott report on file. CL1017540
  3. Olson N, Lo M, Zahwe F, Gururaj A, Martel JA, Bernard ML, Tao C and Venkataraman R. The effect of dynamic mapping data on procedure efficiency in radiofrequency ablation of patients with atrial fibrillation. Abstracts from the 26th Annual International Atrial Fibrillation Symposium. Journal of Cardiovascular Electrophysiology. 2021;32:1467-1515.
  4. Abbott. Data on File. Document 90114565.
  5. Goya M, et al. The use of intracardiac echocardiography catheters in endocardial ablation of cardiac arrhythmia: Meta-analysis of efficiency, effectiveness, and safety outcomes. J Cardiovasc Electrophysiol. 2020;31:664–673.
  6. Abbott. Data on File. Document 90569806.
  7. Bourier, F., Gianni, C., Dare, M., Deisenhofer, I., Hessling, G., Reents, T., . . . Al-Ahmad, A. (2017). Fiberoptic contact-force sensing electrophysiological catheters: how precise is the technology? Journal of Cardiovascular Electrophysiology, 28(1), 109-114.
  8. Bourier F, Deisenhofer I, Hessling G, et al. Contact-force sensing electrophysiological catheters: How accurate is the technology? [Abstract PO03-170]. Presentation at HRS 2016, San Francisco, CA, May 4-7, 2016. Heart Rhythm. 2016;13(5 Suppl 1):S318-S319.
  9. Piorkowski, C., Eitel C., Rolf, S., Bode, K., Sommer, P., Gaspar, T., … Hindricks, G.(2011). Steerable versus non-steerable sheath technology in AF ablation: A prospective, randomized study. Circulation, 4(2), 157-65. https://dx.doi.org/10.1161/CIRCEP.110.957761
  10. Lo MY, Sanders P, Sommer P, Kalman JM, Siddiqui UR, Sundaram S, Piorkowski C, Olson N, Madej SM and Gibson DN. Safety and Effectiveness of a Next-Generation Contact Force Catheter. JACC: Clinical Electrophysiology. 2021;0.
  11. Mansour, M. (2014) TOCCASTAR: Preliminary Results of the First Prospective Randomized Study of a Contact Force Sensing Ablation Catheter for the Treatment of Paroxysmal AF. Presented at HRS 2014. San Francisco, California.
  12. Hildick Smith D et al, Left atrial appendage occlusion with the Amplatzer Amulet device: full results of the prospective global observational study; European Heart Journal 2020;41(30):2894-2901.
  13. Amplatzer Amulet LAA Occluder Instructions for Use.

MAT-2211655 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.



Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.



Do you want to continue? 

YesNo